Sector revisions Merck & Co., Inc.

Equities

Market Closed - Nyse Other stock markets 21:00:40 20/04/2026 BST			5-day change	1st Jan Change
117.10 ^USD	-1.65%		-3.56%	+11.25%

04-20	Merck Announces FDA Grants Priority Review For Keytruda And Keytruda Qlex Each With Padcev For Cisplatin-Eligible Patients With Muscle-Invasive Bladder Cancer	CI
04-20	Merck, Pfizer, Astellas Drug Combo Gets Speedy FDA Review in Bladder Cancer	DJ

Sector:

Location:

X axis:

Main competitors

	Add to a list 0 selected To use this feature you must be a member Log in Sign up	1m. Revenue rev.	4m. EPS revision	4m. Revenue rev.	1y. EPS revision	1y. Revenue rev.	Visibility	Nbr of analysts
	MERCK & CO., INC.							27
	ELI LILLY AND COMPANY							29
	JOHNSON & JOHNSON							24
	ABBVIE INC.							29
	ROCHE HOLDING AG							13
	ASTRAZENECA PLC							21
	NOVARTIS AG							21
	AMGEN INC.							29
	NOVO NORDISK A/S							22
	GILEAD SCIENCES, INC.							28
	PFIZER INC.							27
	BRISTOL-MYERS SQUIBB COMPANY							25
	SANOFI							23
	GSK PLC							20
	VERTEX PHARMACEUTICALS INCORPORATED							29
	CHUGAI PHARMACEUTICAL CO., LTD.							15
	TAKEDA PHARMACEUTICAL COMPANY LIMITED							15
	JIANGSU HENGRUI PHARMACEUTICALS CO.,LTD							17
	BAYER AG							19
	HALEON PLC							17
	Average							22
	Weighted average by Cap.							24